Dalbavancin - CAS 171500-79-1
Catalog number: B0084-169772
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C88H100Cl2N10O28
Molecular Weight:
1816.69
COA:
Inquire
Targets:
Antibacterial
Description:
Dalbavancin is a semi-synthetic glycopeptide by introducing a positively charged lipophilic moiety in a previously unexplored region of the natural glycopeptide. This modification provides a longer in vivo half life, and improved in vitro activity against a variety of Gram positive and multi-drug resistant isolates such as MRSA and MRSE.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-169772 50 mg $198 In stock
Bulk Inquiry
Purity:
>98%
Appearance:
Off-white solid powder
Synonyms:
Ristomycin A aglycone, 5,​31-​dichloro-​38-​de(methoxycarbonyl)​-​7-​demethyl-​19-​deoxy-​56-​O-​[2-​deoxy-​2-​[(10-​methyl-​1-​oxoundecyl)​amino]​-​β-​D-​glucopyranuronosyl]​-​38-​[[[3-​(dimethylamino)​propyl]​amino]​carbonyl]​-​42-​O-​α-​D-​mannopyranosyl-​N15-​methyl-; A-A 1; BI397; BI-397; BI 397; VER 001; VER-001; VER001; MDL63397; MDL-63397; MDL 63397; Dalbavancin Dalbavancin B0; trade name: Dalvance in the US and Xydalba in Europe
MSDS:
Inquire
InChIKey:
PEXPCJWLNBNBNT-AXKGEONOSA-N
InChI:
1S/C88H100Cl2N10O28.ClH/c1-38(2)13-10-8-6-7-9-11-14-61(106)94-70-73(109)75(111)78(86(120)121)128-87(70)127-77-58-31-43-32-59(77)124-55-24-19-42(29-50(55)89)71(107)69-85(119)98-67(80(114)92-25-12-26-100(4)5)48-33-44(102)34-57(125-88-76(112)74(110)72(108)60(37-101)126-88)62(48)47-28-40(17-22-52(47)103)65(82(116)99-69)95-83(117)66(43)96-84(118)68-49-35-46(36-54(105)63(49)90)123-56-30-41(18-23-53(56)104)64(91-3)81(115)93-51(79(113)97-68)27-39-15-20-45(122-58)21-16-39;/h15-24,28-36,38,51,60,64-76,78,87-88,91,101-105,107-112H,6-14,25-27,37H2,1-5H3,(H,92,114)(H,93,115)(H,94,106)(H,95,117)(H,96,118)(H,97,113)(H,98,119)(H,99,116)(H,120,121);1H/t51-,60-,64-,65-,66-,67+,68+,69+,70-,71-,72-,73-,74+,75+,76+,78+,87-,88+;/m1./s1
Canonical SMILES:
CC(CCCCCCCCC(N[C@@H]1[C@@H](O)[C@H](O)[C@@H](C(O)=O)O[C@H]1OC2=C3C=C4C=C2OC5=C(Cl)C=C([C@@H](O)[C@H]6C(N[C@H](C(NCCCN(C)C)=O)C7=CC(O)=CC(O[C@@H]8[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O8)=C7C9=C(O)C=CC([C@@H](NC([C@@H]4NC([C@@H]%10C%11=CC(OC%12=C(O)C=CC([C@@H](NC)C(N[C@@H](C(N%10)=O)CC%13=CC=C(C=C%13)O3)=O)=C%12)=CC(O)=C%11Cl)=O)=O)C(N6)=O)=C9)=O)C=C5)=O)C.Cl
1.Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies.
Dunne MW1, Talbot GH2, Boucher HW3, Wilcox M4,5, Puttagunta S6. Drug Saf. 2016 Feb;39(2):147-57. doi: 10.1007/s40264-015-0374-9.
INTRODUCTION: Dalbavancin is a new lipoglycopeptide that is active against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus. It has a half-life of 14.4 days, permitting intravenous treatment of acute bacterial skin and skin structure infections without the need for daily dosing.
2.Dalbavancin Activity when Tested against Streptococcus pneumoniae Isolated in Medical Centers on Six Continents (2011-2014).
Jones RN1, Schuchert JE2, Mendes RE2. Antimicrob Agents Chemother. 2016 Mar 21. pii: AAC.00116-16. [Epub ahead of print]
Dalbavancin, a novel lipoglycopeptide, was approved in 2014 by regulatory agencies in the United States (USA) and Europe for the treatment of skin and skin structure infections. The activity of dalbavancin was also widely assessed against Streptococcus pneumoniae clinical isolates collected from patients on six continents monitored during two time intervals (2011-2013 and 2014). A total of 18,186 pneumococci were obtained from 49 nations and submitted to a monitoring laboratory as part of the SENTRY Antimicrobial Surveillance Program for reference susceptibility testing. Dalbavancin potency against S. pneumoniae was consistent across the monitored years with a MIC50/90 of 0.015/0.03 μg/ml and all isolates were inhibited at ≤ 0.12 μg/ml. The activity for dalbavancin was not adversely influenced by non-susceptibility to β-lactams (ceftriaxone or penicillin), macrolides, clindamycin, fluoroquinolones, tetracyclines or multidrug-resistance (MDR).
3.Comparative In vitro Activity of Oritavancin, Dalbavancin and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Non-Dividing State.
Belley A1, Lalonde Seguin D1, Arhin F1, Moeck G1. Antimicrob Agents Chemother. 2016 Apr 11. pii: AAC.00169-16. [Epub ahead of print]
Antibacterial agents that kill non-dividing bacteria may be of utility in treating persistent infections. Oritavancin and dalbavancin are bactericidal lipoglycopeptides approved for acute bacterial skin and skin structure infections in adults caused by susceptible gram-positive pathogens. Using time-kill methodology, we demonstrate that oritavancin exerts bactericidal activity against methicillin-resistantStaphylococcus aureus(MRSA) isolates maintained in a non-dividing state in vitro whereas dalbavancin and the glycopeptide vancomycin do not.
4.New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin.
Juul JJ1, Mullins CF1, Peppard WJ1, Huang AM1. Ther Clin Risk Manag. 2016 Feb 16;12:225-32. doi: 10.2147/TCRM.S71855. eCollection 2016.
Dalbavancin, an intravenous glycopeptide, was approved by the US Food and Drug Administration in May 2014 for use in adult patients with acute bacterial skin and skin structure infections. The recommended dosing regimen for effective use of dalbavancin is 1,000 mg followed by a 500 mg dose after 1 week. Two multinational, identically designed, non-inferiority trials, DISCOVER 1 and 2, demonstrated similar early clinical success with dalbavancin compared to vancomycin with an option to switch to oral linezolid. In a recently published non-inferiority trial, a single-dose regimen of dalbavancin was compared to the traditional two-dose administration and was found to have a non-inferior clinical response. In the aforementioned trials, dalbavancin was well tolerated, with patients experiencing transient adverse events of mild to moderate severity. The prolonged half-life, excellent skin and soft tissue penetration, bactericidal activity against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus, and convenient dosing make dalbavancin a reasonable option for the treatment of acute bacterial skin and skin structure infections in adult patients who have tried and failed other therapies.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Antibacterial Products


CAS 115550-35-1 Marbofloxacin

Marbofloxacin
(CAS: 115550-35-1)

Marbofloxacin exhibits high bactericidal activity against a broad spectrum of aerobic Gram-negative and some Gram-positive bacteria, as well as Mycoplasma spp.

CAS 893556-85-9 PF 945863

PF 945863
(CAS: 893556-85-9)

PF 945863, an orally active macrolide antibiotic, is active against multidrug resistant respiratory tract bacterial strains.

Norvancomycin hydrochloride
(CAS: 213997-73-0)

Norvancomycin hydrochloride is an antibacterial agent.

CAS 1404-90-6 Vancomycin

Vancomycin
(CAS: 1404-90-6)

Tricyclic glycopeptide antibiotic. Inhibits cell wall synthesis in Gram-positive bacteria. Pharmacologically active in vivo.

CAS 723-46-6 Sulfamethoxazole

Sulfamethoxazole
(CAS: 723-46-6)

Sulfamethoxazole is a sulfonamide bacteriostatic antibiotic with an IC50 of 2.7 μM.

CAS 68-41-7 D-Cycloserine

D-Cycloserine
(CAS: 68-41-7)

D-Cycloserine is an analog of the amino acid D-alanine.it Inhibits cell wall biosynthesis (D-Ala peptide bond formation) and Also prevents conversion of D-Ala t...

CAS 856866-72-3 Tedizolid

Tedizolid
(CAS: 856866-72-3)

Torezolid is a novel oxazolidinone for gram-positive infections. It was reversible inhibitors of human MAO-A and MAO-B.

CAS 952849-76-2 KKL-10

KKL-10
(CAS: 952849-76-2)

KKL-10 is a small-molecule ribosome rescue inhibitor with exceptional antimicrobial activity against both attenuated and fully virulent strains of F. tularensis...

Chemical Structure

CAS 171500-79-1 Dalbavancin

Quick Inquiry

Verification code

Featured Items